steroid-free clinical remission at week 52.
Upadacitinib was also effective in treating ulcerative colitis patients at a low maintenance dose of 30 mg or 15 mg for those with less severe disease, according to Brian Feagan, MD, gastroenterologist at the Division of Gastroenterology at Western University, in London, Ontario.